Literature DB >> 16254493

TLR and NOD2 ligands induce cell proliferation in the rat intact spinal cord.

Yanhua Su1, Zhiren Zhang, Katrin Trautmann, Shunqing Xu, Hermann J Schluesener.   

Abstract

We demonstrate, by 5-bromo-2'-deoxyuridine (BrdU) tracing, the effects of peripheral administration of toll-like receptor (TLR) and NOD2 ligands (stimulators of the innate immune system) on the proliferation of spinal cord cells. Bolus injection of phosphorothioate oligonucleotides containing CpG motifs had no prominent effects on spinal cord neural progenitor cell proliferation, whereas single intraperitoneal injection of polyinosine-polycytidylic acid (Poly I:C, TLR3 ligand), lipopolysaccharide (LPS, TLR4 ligand), R848 (TLR7/8 ligand), or N-acetylmuramyldipeptide (MDP, Nod2 ligand) temporarily increased the number of BrdU(+) cells in the spinal cord. For Poly I:C- or R848-treated groups, the density of BrdU cells reached maximal levels on days 2 to 3 postinjection and then rapidly declined to baseline levels. Only a few of the proliferating cells were of microglial origin, but BrdU(+)/nestin(+) cells were found, suggestive of a proliferation of local progenitor cells. In addition, stimulation of cell proliferation correlated with activation of the innate immune system, that is, microglial cells. Interestingly, activation and cell proliferation was inhibited by corticosteroid dexamethasone but not by indomethacin. These findings suggest an intricate interaction of phylogenetically ancient cellular processes of the innate immune system and regeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254493     DOI: 10.1097/01.jnen.0000187051.74265.56

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  6 in total

Review 1.  NLRs in immune privileged sites.

Authors:  Holly L Rosenzweig; Stephen R Planck; James T Rosenbaum
Journal:  Curr Opin Pharmacol       Date:  2011-07-29       Impact factor: 5.547

Review 2.  Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential.

Authors:  Mark L Hanke; Tammy Kielian
Journal:  Clin Sci (Lond)       Date:  2011-11       Impact factor: 6.124

3.  Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals.

Authors:  Jill S Cameron; Lena Alexopoulou; Jacob A Sloane; Allitia B DiBernardo; Yinghua Ma; Bela Kosaras; Richard Flavell; Stephen M Strittmatter; Joseph Volpe; Richard Sidman; Timothy Vartanian
Journal:  J Neurosci       Date:  2007-11-21       Impact factor: 6.167

Review 4.  Dysregulation of neurogenesis by neuroinflammation: key differences in neurodevelopmental and neurological disorders.

Authors:  Lir-Wan Fan; Yi Pang
Journal:  Neural Regen Res       Date:  2017-03       Impact factor: 5.135

5.  Distinct trans-placental effects of maternal immune activation by TLR3 and TLR7 agonists: implications for schizophrenia risk.

Authors:  Jonathan Cavanagh; Brian J Morris; Jaedeok Kwon; Maria Suessmilch; Alison McColl
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

6.  Activation of Toll-like receptor 5 in microglia modulates their function and triggers neuronal injury.

Authors:  Masataka Ifuku; Lukas Hinkelmann; Leonard D Kuhrt; Ibrahim E Efe; Victor Kumbol; Alice Buonfiglioli; Christina Krüger; Philipp Jordan; Marcus Fulde; Mami Noda; Helmut Kettenmann; Seija Lehnardt
Journal:  Acta Neuropathol Commun       Date:  2020-09-10       Impact factor: 7.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.